Safety Profile of the Fluoroquinolones (original) (raw)

• Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118(3): 259–68
  Article PubMed Google Scholar
• Ball P, Mandell L. Treatment of community-acquired respiratory tract infections. In: Hooper D, Rubinstein E, editors. Quinolone antimicrobial agents. Washington, DC: American Society of Microbiology Press, 2003: 227–43
  Google Scholar
• Andriole VT. The future of the quinolones. Drugs 1999; 58 Suppl. 2: 1–5
  Article PubMed CAS Google Scholar
• King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician 2000; 61(9): 2741–8
  PubMed CAS Google Scholar
• European Medicines Agency. Public statement on Trovan/ Trovan IV/Turvel/Turvel IV (trovafloxacin/alatrofloxacin): serious, severe and unpredictable liver injuries. London: European Medicines Agency, 1999 May 25 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pus/1577099EN.pdf [Accessed 2010 Mar 30]
• US FDA. Trovan (trovafloxacin/alatrofloxacin mesylate): interim recommendations. Rockville (MD): US FDA, 1999 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/UCM053103 [Accessed 2010 Mar 11]
• Levofloxacin (Levaquin) package insert. Raritan (NJ): Ortho-McNeil-Janssen, 2008
• Ball P. Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr Ther Res Clin Exp 2003; 64(9): 646–61
  Article CAS Google Scholar
• Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47(4): 677–700
  Article PubMed CAS Google Scholar
• Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28(2): 352–64
  Article PubMed CAS Google Scholar
• Mandell L, Tillotson G. Safety of fluoroquinolones: an update. Can J Infect Dis 2002; 13(1): 54–61
  PubMed CAS Google Scholar
• Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 Suppl. 2: S144–57
  Article PubMed CAS Google Scholar
• Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J 1994; 87(9): 869–74
  Article PubMed CAS Google Scholar
• Stahlmann R. Safety profile of the quinolones. J Anti-microb Chemother 1990; 26 Suppl. D: 31–44
  Article CAS Google Scholar
• Ciprofloxacin [Cipro] package insert. Kenilworth (NJ): Schering Corporation, 2009
• Moxifloxacin [Avelox] package insert. Kenilworth (NJ): Schering Corporation, 2008
• Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35(10): 1194–8
  Article PubMed CAS Google Scholar
• Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32(5): 359–78
  Article PubMed Google Scholar
• Bellon A, Perez-Garcia G, Coverdale JH, et al. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol 2009; 65(10): 959–62
  Article PubMed CAS Google Scholar
• Hori S, Kizu J, Kawamura M. Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J Infect Chemother 2003; 9(4): 314–20
  Article PubMed CAS Google Scholar
• Shrivastava MP, Makde SD, Paranjpe BD. Interaction of ciprofloxacin with diclofenac and paracetamol in relation to its epileptogenic effect. Indian J Physiol Pharmacol 1997; 41(2): 164–6
  PubMed CAS Google Scholar
• Bryskier A, Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995; 49 Suppl. 2: 16–28
  Article PubMed CAS Google Scholar
• Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials [published erratum appears in J Antimicrob Chemother 1994 Nov; 34 (5): 851]. J Antimicrob Chemother 1994; 33(4): 685–706
  Article PubMed CAS Google Scholar
• Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42(7): 1831–6
  PubMed CAS Google Scholar
• Akahane K, Kato M, Takayama S. Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice. Antimicrob Agents Chemother 1993; 37(9): 1764–70
  Article PubMed CAS Google Scholar
• Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41(9): 1254–60
  Article PubMed CAS Google Scholar
• von Baum H, Sigge A, Bommer M, et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006; 58(4): 891–4
  Article Google Scholar
• Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38(5): 640–5
  Article PubMed Google Scholar
• Liu HH. Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia. Curr Ther Res 2004; 65(3): 225–38
  Article CAS Google Scholar
• Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65(3): 455–64
  PubMed Google Scholar
• Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353(23): 2442–9
  Article PubMed CAS Google Scholar
• Mendez MN, Gibbs L, Jacobs RA, et al. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant Enterococci and Clostridium difficile infections. Pharmacotherapy 2006; 26(1): 61–7
  Article PubMed Google Scholar
• Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47 Suppl. 3: 3–8, discussion 44–8
  Article PubMed CAS Google Scholar
• Andriole VT. The quinolones: past, present, and future. Clin Infect Dis 2005; 41 Suppl. 2: S113–9
  Article PubMed CAS Google Scholar
• Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26(7): 940–50
  Article PubMed CAS Google Scholar
• File TM, Iannini PB. A profile of gemifloxacin, a new respiratory fluoroquinolone. Todays Ther Trends 2003; 21: 415–35
  Google Scholar
• Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003; 37(9): 1210–5
  Article PubMed CAS Google Scholar
• Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am 2000; 84: 1447–69
  Article PubMed CAS Google Scholar
• Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41(11): 1859–66
  Article PubMed CAS Google Scholar
• Shantsila E, Watson T, Lip GY. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 2007; 9 Suppl. 4: iv37–44
  Article PubMed Google Scholar
• Pollard CE, Valentin JP, Hammond TG. Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 2008; 154(7): 1538–43
  Article PubMed CAS Google Scholar
• Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81(2): 299–307
  Article PubMed CAS Google Scholar
• Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29(4): 374–9
  Article PubMed CAS Google Scholar
• Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59(1): 122–6
  PubMed CAS Google Scholar
• Bischoff U, Schmidt C, Netzer R, et al. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000; 406(3): 341–3
  Article PubMed CAS Google Scholar
• Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296(3): 806–10
  PubMed CAS Google Scholar
• Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49(4): 593–6
  Article PubMed CAS Google Scholar
• Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15(4): 475–95
  Article PubMed Google Scholar
• Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21(15): 1216–31
  Article PubMed CAS Google Scholar
• Lannini PB, Circiumaru I. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy 2001; 21(3): 361–2
  Article PubMed CAS Google Scholar
• Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11(1): 52–6
  Article PubMed Google Scholar
• Makaryus AN, Byrns K, Makaryus MN, et al. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant “clinical” event? South Med J 2006; 99(1): 52–6
  Article PubMed Google Scholar
• Noel GJ, Goodman DB, Chien S, et al. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004; 44(5): 464–73
  Article PubMed CAS Google Scholar
• Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73(4): 292–303
  Article PubMed CAS Google Scholar
• Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68(6): 658–66
  Article PubMed CAS Google Scholar
• Kahn JB. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000; 46(5): 847–8
  Article PubMed CAS Google Scholar
• Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000; 45(5): 557–9
  Article PubMed CAS Google Scholar
• Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128(5): 3398–406
  Article PubMed CAS Google Scholar
• Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001; 21(12): 1468–72
  Article PubMed CAS Google Scholar
• Shaffer DN, Singer SJ. Macrolide antibiotics and torsade de pointes postmarketing analysis [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/slides/3746s_02_Shaffer/sld001htm [Accessed 2009 Aug 11]
• Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269(21): 2765–8
  Article PubMed CAS Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29(5): 385–96
  Article PubMed Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354(13): 1352–61
  Article PubMed CAS Google Scholar
• Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005; 25(10): 1303–9
  Article PubMed CAS Google Scholar
• Hori S, Kizu J, Kawamura M. Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice. J Infect Chemother 2006; 12(2): 109–11
  Article PubMed CAS Google Scholar
• Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005; 25(10): 1296–302
  Article PubMed CAS Google Scholar
• Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497(1): 111–7
  Article PubMed CAS Google Scholar
• Lodise T, Graves J, Miller C, et al. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyper-glycemia among elderly hospitalized patients. Pharmacotherapy 2007; 27(11): 1498–505
  Article PubMed CAS Google Scholar
• Gavin IJR, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004; 27(9): 671–86
  Article PubMed CAS Google Scholar
• McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther 1995; 66(3): 465–505
  Article PubMed CAS Google Scholar
• Ge TF, Law PY, Wong HY, et al. Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. Eur J Pharmacol 2007; 573(1–3): 70–4
  Article PubMed CAS Google Scholar
• Yamada C, Nagashima K, Takahashi A, et al. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 2006; 553(1–3): 67–72
  Article PubMed CAS Google Scholar
• Mohr III JF, Peymann PJ, Troxell E, et al. Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis. Clin Ther 2008; 30(1): 152–7
  Article PubMed CAS Google Scholar
• Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52(3): 435–40
  Article PubMed CAS Google Scholar
• Ge DT, Law PY, Kong SK, et al. Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett 2009; 184(2): 81–4
  Article PubMed CAS Google Scholar
• Lewis RJ, Mohr III JF. Dysglycaemias and fluoroquinolones. Drug Saf 2008; 31(4): 283–92
  Article PubMed CAS Google Scholar
• Blayac JP, Hillaire-Buys D, Pinzani V. Fluoroquinolones and anaphylaxis. Therapie 1996; 51(4): 417–8
  PubMed CAS Google Scholar
• Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29(11): 1087–100
  Article PubMed CAS Google Scholar
• Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf 2007; 30(8): 705–13
  Article PubMed Google Scholar
• Cutaneous drug reaction case reports: from the world literature. Am J Clin Dermatol 2002; 3 (7): 509–16
• Springsklee M, Reiter C, Mayer JM. Safety and tolerability profile of moxifloxacin (MXF) [abstract P0208]. Clin Microbiol Infect 1999; 5 Suppl. 3: 140
  Article Google Scholar
• Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996; 37 Suppl. A: 145–60
  Article PubMed CAS Google Scholar
• _Lipsky BA, Dorr MB, Magner DJ, et al. Safety profile of sparfloxacin in North American phase III clinical trials [abstract no LM-57]. Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans (LA). Washington, DC: American Society for Microbiology, 1996
  Google Scholar
• Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160(18): 2819–22
  Article PubMed CAS Google Scholar
• Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J 2001; 94(8): 817–24
  PubMed CAS Google Scholar
• Nori S, Nebesio C, Brashear R, et al. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. Arch Dermatol 2004; 140(12): 1537–8
  Article PubMed Google Scholar
• Iannini P, Mandell L, Felmingham J, et al. Adverse cutaneous reactions and drugs: a focus on antimicrobials. J Chemother 2006; 18(2): 127–39
  PubMed CAS Google Scholar
• Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333(24): 1600–7
  Article PubMed CAS Google Scholar
• Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21(5): 407–21
  Article PubMed CAS Google Scholar
• De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24(8): 1187–95
  Article PubMed CAS Google Scholar
• Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156(12): 1327–32
  Article PubMed CAS Google Scholar
• Perez Gutthann S, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4(6): 496–501
  Article PubMed CAS Google Scholar
• European Medicines Agency. European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines [press release]. London: European Medicines Agency Press Office, 2008 Jul 24 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/press/pr/38292708en.pdf [Accessed 20100 Mar 30]
• Fleisch F, Hartmann K, Kuhn M. Fluoroquinolone-induced tendinopathy: also occurring with levofloxacin. Infection 2000; 28(4): 256–7
  Article PubMed CAS Google Scholar
• van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324(7349): 1306–7
  Article PubMed Google Scholar
• Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Saf 2003; 26(2): 109–20
  Article PubMed CAS Google Scholar
• van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163(15): 1801–7
  Article PubMed Google Scholar
• Burkhardt O, Kohnlein T, Pap T, et al. Recurrent tendinitis after treatment with two different fluoroquinolones. Scand J Infect Dis 2004; 36(4): 315–6
  Article PubMed Google Scholar
• Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006; 118(3): 1287–92
  Article Google Scholar
• Burkhardt JE, Hill MA, Carlton WW, et al. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990; 27(3): 162–70
  Article PubMed CAS Google Scholar
• Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10 Suppl. 1: S141–6
  Article PubMed CAS Google Scholar
• Kato M, Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam Appl Toxicol 1988; 11(1): 110–9
  Article PubMed CAS Google Scholar
• Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003; 22(12): 1128–32
  Article PubMed Google Scholar
• Burstein GR, Berman SM, Blumer JL, et al. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? Clin Infect Dis 2002; 35 Suppl. 2: S191–9
  Article PubMed CAS Google Scholar
• Yee CL, Duffy C, Gerbino PG, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002; 21(6): 525–9
  Article PubMed Google Scholar
• Avalox (Moxifloxacin): summary of product characteristics. Kenilworth (NJ): Schering Corporation, 2006
• Tavanic (Levofloxacin) UK package insert. Guildford: Sanofi-aventis, 2006
• Ciprofloxacin 2 mg/mL infusion: summary of product characteristics. Kenilworth (NJ): Schering Corporation, 2006
• Ciproxin (Ciprofloxacin) tablets 500 mg: summary of product characteristics. Kenilworth (NJ): Schering Corporation, 2008
• Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2001; 27(3): 193–209
  Article Google Scholar
• Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34(3): 453–68
  Article PubMed CAS Google Scholar
• Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996; 14(2): 69–77
  Article PubMed CAS Google Scholar
• Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones: a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143(2): 75–8
  Article PubMed CAS Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350(10): 1013–22
  Article PubMed CAS Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89(11): 1363–72
  Article PubMed CAS Google Scholar
• Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7(6): 639–51
  Article PubMed CAS Google Scholar
• Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000; 63(1): 28–31
  Article PubMed CAS Google Scholar
• Martin SJ, Sahloff EG, Close SJ. Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections. Expert Opin Pharmacother 2002; 3(9): 1251–66
  Article PubMed Google Scholar